Comparision | Odds ratio (meta-analysis) | 95% CI | Method of analysis | Number of studies included in the sub-meta-analysis | Forest plot |
---|---|---|---|---|---|
ACEI to ARBs | 0.94 | 0.84–1.04 | MH | 16 | Figure S1 |
ACEIs to BBs | 0.85 | 0.73–0.99 | MH | 7 | Figure S2 |
ACEIs to CCBs | 0.91 | 0.67–1.23 | RE | 8 | Figure S3 |
ACEIs to Thiazides | 1.22 | 1.02–1.45 | MH | 6 | Figure S4 |
ACEIs to all other antihypertensives | 0.91 | 0.84–0.99 | MH | 16 | Figure S5 |
ARBs to all other antihypertensives | 0.98 | 0.83–1.17 | RE | 16 | Figure S6 |
ARBs to BBs | 0.72 | 0.55–0.94 | RE | 7 | Figure S7 |
ARBs to CCBs | 0.90 | 0.62–1.33 | RE | 8 | Figure S8 |
ARBs to Thiazides | 1.15 | 0.97–1.37 | MH | 6 | Figure S9 |
ARBs to all other non-RAAS antihypertensives | 0.89 | 0.71–1.12 | RE | 11 | Figure S10 |
ACEIs to all other non-RAAS antihypertensives | 0.89 | 0.74–1.06 | RE | 11 | Figure S11 |
CCBs to ACEI, ARBs, BBs | 0.95 | 0.68–1.33 | RE | 10 | Figure S12 |
ACEI, ARBs, BBs to CCBs and thiazides | 1.13 | 0.87–1.47 | RE | 10 | Figure S13 |